On March 29th, 2023, TaiMed entered into a 10-year exclusive sales and marketing agreement with Meroven Limited, an Irish company, for the HIV drug Trogarzo in the Middle East and North Africa regions. According to the contract terms, Meroven will be responsible for the regulatory application process and sales operations related to the specified countries and regions.

Due to Meroven's failure to actively pursue regulatory applications and product sales in the authorized regions as stipulated in the agreement over the past years, thereby violating significant obligations under the agreement, the TaiMed Board of Directors has resolved to consider terminating the exclusive sales and marketing agreement for the HIV drug Trogarzo in the Middle East and North Africa regions with Meroven Limited.

Future demand for Trogarzo in that region will be met through a "Post-Approval Named Patient Program" (PA-NPP), which will cater to the medication needs of patients with multiple drug-resistant HIV/AIDS.

Back to the top